DHODH

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

Retrieved on: 
Tuesday, June 7, 2022
The Company, Anesthesiology, Johns Hopkins School of Medicine, Company, Research, Doctor of Philosophy, Associate, DHODH, ASLN, LinkedIn, Disease, Nasdaq, Skin, Commission, Allergy, Prurigo nodularis, GLOBE, Patient, Publication, Review, Duke University Hospital, Projection, Atopic dermatitis, COVID-19, Psoriasis, Autoimmune disease, NASDAQ, MD, Clinical trial, Board, Department, U.S. Securities and Exchange Commission, Safety, Pharmaceutical industry, Medical device, Dermatology

Initial findings from the collaboration will be disclosed for presentation during the second half of 2022.

Key Points: 
  • Initial findings from the collaboration will be disclosed for presentation during the second half of 2022.
  • His areas of clinical expertise include atopic dermatitis, chronic pruritus, prurigo nodularis and dermatology for ethnic skin.
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
  • These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company").

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Retrieved on: 
Tuesday, June 7, 2022
Cohort, Degenerative disease, Steroid, Ulcerative colitis, Headache, RMS, Program, Conference, Observation, Anemia, DHODH, Nature, Security (finance), U.S. Securities and Exchange Commission, Primary sclerosing cholangitis, Nasdaq, RRMS, Metabolism, PMS, Patient, AFL, Private Securities Litigation Reform Act, Psoriasis, COVID-19, Calcium, Immune system, SEC, NEW, Population, Clinical trial, Infection, Drug development, Weaning, Safety, Dietary supplement, Pharmaceutical industry, Vaccine, Short course immune induction therapy, UC, Webcast, Multiple sclerosis

Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was observed to be safe and well-tolerated.

Key Points: 
  • Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was observed to be safe and well-tolerated.
  • The most common adverse events in this trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%).
  • This treatment interference between vidofludimus calcium and corticosteroids was not expected by currently available preclinical or clinical data.
  • Patient enrollment in both the phase 3 ENSURE program of vidofludimus calcium in patients with RMS and the phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS remain ongoing.

ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’

Retrieved on: 
Monday, June 6, 2022
Faculty, Pediatrics, Boston, Archives of Disease in Childhood, Harvard Medical School, DHODH, Titles of distinction awarded by the University of Oxford, ASLN, LinkedIn, American Academy, CEO, Atopic dermatitis, Museum, Beth Israel Deaconess Medical Center, Inflammation, Itch, Nasdaq, American Academy of Dermatology, GLOBE, Patient, AD, Alternative, Publication, Harvard University, KOL, Autoimmune disease, MD, Self-signed certificate, Board, Hospital, MPH, Safety, Fine chemical, Medical device, Medicine, Pharmaceutical industry, Doctor of Philosophy, Dermatology, Northwestern University, Medicine, Northwestern

The webinar will feature a presentation by Dr Lio on the limitations of the current treatment landscape in AD and the resulting unmet medical needs.

Key Points: 
  • The webinar will feature a presentation by Dr Lio on the limitations of the current treatment landscape in AD and the resulting unmet medical needs.
  • Dr Lio obtained his medical degree from Harvard Medical School where he completed his dermatology training and served as Chief Resident in Dermatology.
  • ASLANs A4 webinar series: Dialogues with International Thought Leaders in Dermatology is a series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) landscape and ASLAN004.
  • ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Retrieved on: 
Thursday, June 2, 2022
Cohort, Degenerative disease, Steroid, Ulcerative colitis, Headache, RMS, Program, Observation, Anemia, DHODH, Annual report, Nature, Webcast, Security (finance), U.S. Securities and Exchange Commission, Primary sclerosing cholangitis, RRMS, Metabolism, Risk, PMS, Patient, AFL, Private Securities Litigation Reform Act, Psoriasis, COVID-19, Calcium, Immune system, SEC, NEW, Population, Prednisolone, Clinical trial, Infection, Drug development, Weaning, Safety, Dietary supplement, Pharmaceutical industry, Vaccine, Short course immune induction therapy, UC, Multiple sclerosis

Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was observedto besafe and well-tolerated.

Key Points: 
  • Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was observedto besafe and well-tolerated.
  • The most common adverse eventsin this trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%).
  • This treatment interference between vidofludimus calcium and corticosteroids was not expected by currently available preclinical or clinical data.
  • Patient enrollment in both the phase 3 ENSURE program of vidofludimus calcium in patients with RMS and the phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS remain ongoing.

ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

Retrieved on: 
Friday, May 20, 2022
Cannabinoid receptor type 2, Company, Disease, Dorsal root ganglion, U.S. Securities and Exchange Commission, Clinical and Translational Science, Nasdaq, Patient, SID, Quality of life, DHODH, Review, Cytokine, Clinical trial, Commission, COVID-19, AD, ASLN, Neuron, Projection, Autoimmune disease, Safety, Pathology, Society, LinkedIn, The Company, GLOBE, Atopic dermatitis, Pharmaceutical industry, Fine chemical

Chronic itch is a hallmark and major symptom of atopic dermatitis and other tType 2-driven inflammatory skin disorders.

Key Points: 
  • Chronic itch is a hallmark and major symptom of atopic dermatitis and other tType 2-driven inflammatory skin disorders.
  • In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients.
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
  • These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company").

ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
Nasdaq, Patient, NASDAQ, DHODH, Investor, ASLN, Conference, Autoimmune disease, LinkedIn, GLOBE, CEO, Atopic dermatitis, Pharmaceutical industry

MENLO PARK, Calif. and SINGAPORE, May 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. WainwrightGlobal Investment Conference.

Key Points: 
  • MENLO PARK, Calif. and SINGAPORE, May 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. WainwrightGlobal Investment Conference.
  • The conference will be held virtually and in-person from May 23 to 26, 2022.
  • ASLAN management will also be available for virtual one-on-one meetings throughout the conference.
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting

Retrieved on: 
Tuesday, May 10, 2022
SID, Society, AD, Nasdaq, NASDAQ, GLOBE, DHODH, Clinical and Translational Science, Safety, Patient, Autoimmune disease, Atopic dermatitis, Neuron, Inflammation, Investor relations, ASLN, LinkedIn, Itch, Pharmaceutical industry

IL-4 and IL-13 are central to the pathogenesis of atopic dermatitis, exacerbate inflammation and exert neuronal enhancer function to itch.

Key Points: 
  • IL-4 and IL-13 are central to the pathogenesis of atopic dermatitis, exacerbate inflammation and exert neuronal enhancer function to itch.
  • The poster will be available to view online in the Investor Relations section of ASLANs website following presentation: https://ir.aslanpharma.com/ .
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
  • For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn .

DGAP-News: Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Drug development, U.S. Securities and Exchange Commission, Irritable bowel syndrome, Bloating, Diarrhea, Private Securities Litigation Reform Act, Immune system, Ulcerative colitis, Malabsorption, Nasdaq, Pharmacokinetics, DHODH, Fatigue, Multiple sclerosis, NEW, Safety, Degenerative disease, Metabolism, Patient, Autoimmune disease, Abdominal pain, Security (finance), Coeliac disease, Clinical trial, Inflammatory bowel disease, Inflammation, Anemia, Patent, Primary sclerosing cholangitis, Daiichi Sankyo, Osteoporosis, Quality of life, Regeneration, Weight loss, SEC, Psoriasis, Gastrointestinal tract, Nutrient, Cancer, Growth, Risk, Nature, Pharmaceutical industry, Dietary supplement, Vaccine, Part, Short course immune induction therapy

Because it represents a significant unmet need with well characterized surrogate markers of disease activity, we believe that celiac disease is an ideal initial clinical indication to provide proof-of-concept of IMU-856s acute and chronic impact.

Key Points: 
  • Because it represents a significant unmet need with well characterized surrogate markers of disease activity, we believe that celiac disease is an ideal initial clinical indication to provide proof-of-concept of IMU-856s acute and chronic impact.
  • Celiac disease is a life-long and serious autoimmune disease of the small bowel whose pathophysiology is due to gluten-induced damage to the intestinal barrier.
  • Parts A and B of the ongoing phase 1 clinical trial are evaluating single and multiple ascending doses of IMU-856 in healthy human subjects.
  • In November 2018, Immunic and Daiichi Sankyo entered into a global option and license agreement, granting Immunic the exclusive right to license IMU-856.

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, Drug development, Crohn's disease, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Ulcerative colitis, DHODH, NEW, Metabolism, Security (finance), Clinical trial, Risk, Annual report, Degenerative disease, Primary sclerosing cholangitis, SEC, Psoriasis, Multiple sclerosis, Nature, Vaccine, Short course immune induction therapy, Webcast

NEW YORK, May 3, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2022, including a corporate update, on Tuesday, May 10, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Key Points: 
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations .
  • Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
  • IMU-935, a selective inverse agonist of the transcription factor ROR/RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome.
  • IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

DGAP-News: Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

Retrieved on: 
Monday, April 25, 2022
Drug development, Ulcerative colitis, Primary sclerosing cholangitis, Technology, Clinical trial, Ophthalmology, Multiple sclerosis, COVID-19, U.S. Securities and Exchange Commission, Security (finance), DDW, Annual report, Psoriasis, Private Securities Litigation Reform Act, Risk, Conference, Metabolism, SEC, Innovation, NEW, Degenerative disease, Crohn's disease, Industry, CEST, DHODH, Pharmaceutical industry, Vaccine, Short course immune induction therapy

Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat on Wednesday, April 27, at 9:30 am ET.

Key Points: 
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat on Wednesday, April 27, at 9:30 am ET.
  • A live webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • An archived replay will be available on the company's website for a period of one year after the conference.
  • Examples of such statements include, but are not limited to, statements relating to management's participation in investor and industry conferences.